Discontinued — last reported Q3 '25
Equity
Common Stock
Alnylam Pharmaceuticals Common Stock increased by 18782.2% to 250M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from 250M to 250M. Over 5 years (FY 2020 to FY 2025), Common Stock shows an upward trend with a 2.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ3 2025
How to read this metric
Changes are typically driven by share issuances or buybacks, reflecting capital allocation decisions.
Detailed definition
This represents the par value of the common shares issued by the company. It is a component of shareholders' equity and...
Peer comparison
A standard equity line item found on the balance sheets of all publicly traded companies.
Metric ID:
common_stockHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 250M | 250M | 250M | 250M | 250M | 250M | 1.2M | 250M | 250M | 250M | 1.3M | 250M | 250M | 250M | 1.3M | 250M | 250M | 250M | 1.3M | 250M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -99.5% | >999% | +0.0% | +0.0% | -99.5% | >999% | +0.0% | +0.0% | -99.5% | >999% | +0.0% | +0.0% | -99.5% | >999% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | -99.5% | +0.0% | +0.0% | +0.0% | +1.5% | +0.0% | +0.0% | +0.0% | +2.7% | +0.0% | +0.0% | +0.0% | +2.4% | +0.0% |
Range1.2M – 250M
CAGR+0.0%
Avg YoY Growth-5.8%
Median YoY Growth+0.0%
Common Stock at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's common stock?
- Alnylam Pharmaceuticals (ALNY) reported common stock of 250M in Q1 2026.
- How has Alnylam Pharmaceuticals's common stock changed year-over-year?
- Alnylam Pharmaceuticals's common stock decreased by 0.0% year-over-year, from 250M to 250M.
- What is the long-term trend for Alnylam Pharmaceuticals's common stock?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's common stock has grown at a 2.6% compound annual growth rate (CAGR), from 1.2M to 1.3M.
- What does common stock mean?
- The accounting value of the company's issued common shares.